Method of identifying polypeptide monobodies which bind to target proteins and use thereof
First Claim
1. A fibronectin type III (Fn3) polypeptide monobody comprising:
- at least two Fn3 β
-strand domain sequences with a loop region sequence linked between adjacent β
-strand domain sequences; and
optionally, an N-terminal tail of at least about 2 amino acids, a C-terminal tail of at least about 2 amino acids, or both;
wherein at least one loop region sequence, the N-terminal tail, or the C-terminal tail comprises an amino acid sequence which varies by deletion, insertion, or replacement of at least two amino acids from a corresponding loop region, N-terminal tail, or C-terminal tail in a wild-type Fn3 domain of fibronectin, and wherein the polypeptide monobody exhibits nuclear receptor binding activity.
2 Assignments
0 Petitions
Accused Products
Abstract
A method of identifying a polypeptide monobody having target protein binding activity, said method comprising: providing a host cell comprising (i) a reporter gene under control of a 5′ regulatory region operable in the host cell, (ii) a first chimeric gene which encodes a first fusion polypeptide comprising a target protein, or fragment thereof, fused to a C-terminus of a DNA-binding domain which binds to the 5′ regulatory region of the reporter gene, and (iii) a second chimeric gene which encodes a second fusion polypeptide comprising a polypeptide monobody fused to a transcriptional activation domain; and detecting expression of the reporter gene, which indicates binding of the polypeptide monobody of the second fusion polypeptide to the target protein such that the transcriptional activation domain of the second fusion polypeptide is in sufficient proximity to the DNA-binding domain of the first fusion polypeptide to allow expression of the reporter gene.
-
Citations
108 Claims
-
1. A fibronectin type III (Fn3) polypeptide monobody comprising:
-
at least two Fn3 β
-strand domain sequences with a loop region sequence linked between adjacent β
-strand domain sequences; and
optionally, an N-terminal tail of at least about 2 amino acids, a C-terminal tail of at least about 2 amino acids, or both;
wherein at least one loop region sequence, the N-terminal tail, or the C-terminal tail comprises an amino acid sequence which varies by deletion, insertion, or replacement of at least two amino acids from a corresponding loop region, N-terminal tail, or C-terminal tail in a wild-type Fn3 domain of fibronectin, and wherein the polypeptide monobody exhibits nuclear receptor binding activity. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
-
22. A combinatorial library comprising:
-
a plurality of fusion polypeptides each comprising a transcriptional activation domain fused to a distinct fibronectin type III (Fn3) polypeptide monobody, the polypeptide monobody comprising (i) at least two Fn3 β
-strand domain sequences, (ii) a loop region sequence linked between adjacent β
-strand domain sequences, and (iii) optionally, an N-terminal tail of at least about 2 amino acids, a C-terminal tail of at least about 2 amino acids, or both,wherein at least one loop region sequence, the N-terminal tail, or the C-terminal tail comprises a combinatorial amino acid sequence which varies by deletion, insertion, or replacement of at least two amino acids from a corresponding loop region, N-terminal tail, or C-terminal tail in a wild-type Fn3 domain of fibronectin. - View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)
-
-
44. A method of identifying a polypeptide monobody having target protein binding activity, said method comprising:
-
providing a host cell comprising (i) a reporter gene under control of a 5′
regulatory region operable in the host cell, (ii) a first chimeric gene which encodes a first fusion polypeptide comprising a target protein, or fragment thereof, fused to a C-terminus of a DNA-binding domain which binds to the 5′
regulatory region of the reporter gene, and (iii) a second chimeric gene which encodes a second fusion polypeptide comprising a polypeptide monobody fused to a transcriptional activation domain; and
detecting expression of the reporter gene, which indicates binding of the polypeptide monobody of the second fusion polypeptide to the target protein such that the transcriptional activation domain of the second fusion polypeptide is in sufficient proximity to the DNA-binding domain of the first fusion polypeptide to allow expression of the reporter gene. - View Dependent Claims (45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)
-
-
58. A method of screening a candidate drug for nuclear receptor agonist or antagonist activity, said method comprising:
-
providing a host cell comprising (i) a reporter gene under control of a 5′
regulatory region, (ii) a first chimeric gene which encodes a first fusion polypeptide comprising a nuclear receptor, or fragment thereof including a ligand-binding domain, fused to a C-terminus of a DNA-binding domain which binds to the 5′
regulatory region of the reporter gene, and (iii) a second chimeric gene which encodes a second fusion polypeptide comprising a polypeptide sequence fused to a transcriptional activation domain, the polypeptide sequence binding to the nuclear receptor, or fragment thereof, in the absence of both an agonist and an antagonist of the nuclear receptor, presence of an agonist of the nuclear receptor, presence of an antagonist of the nuclear receptor, or presence of both an agonist and an antagonist of the nuclear receptor;
growing the host cell in a growth medium comprising a candidate drug; and
detecting expression of the reporter gene, which indicates binding of the polypeptide sequence of the second fusion polypeptide to the nuclear receptor, or fragment thereof, such that the transcriptional activation domain of the second fusion polypeptide is in sufficient proximity to the DNA-binding domain of the first fusion polypeptide to allow expression of the reporter gene, wherein modulation of reporter gene expression indicates that the candidate drug is either an agonist or an antagonist, or has mixed activity. - View Dependent Claims (59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)
-
-
76. A kit comprising:
a culture system which includes a culture medium on which has been placed at least one transformed host cell, each of the at least one transformed host cell comprising (i) a reporter gene under control of a 5′
regulatory region, (ii) a first chimeric gene which encodes a first fusion polypeptide comprising a nuclear receptor, or fragment thereof including a ligand-binding domain, fused to a C-terminus of a DNA-binding domain which binds to the 5′
regulatory region of the reporter gene, and (iii) a second chimeric gene which encodes a second fusion polypeptide comprising a polypeptide sequence fused to a transcriptional activation domain, the polypeptide sequence binding to the nuclear receptor, or fragment thereof, in the absence of both an agonist and an antagonist of the nuclear receptor, presence of an agonist of the nuclear receptor, presence of an antagonist of the nuclear receptor, or presence of both an agonist and an antagonist of the nuclear receptor.- View Dependent Claims (77, 78, 79, 80, 81, 82, 83)
-
84. A kit comprising:
-
a plurality of host cells, each comprising a reporter gene under control of a 5′
regulatory region and a heterologous DNA molecule encoding a first fusion polypeptide comprising a nuclear receptor, or fragment thereof which includes a ligand-binding domain, fused to a C-terminus of a DNA-binding domain which binds to the 5′
regulatory region of the reporter gene; and
a vector comprising a DNA molecule encoding a second fusion polypeptide comprising a transcriptional activation domain fused to a polypeptide monobody;
wherein, upon mutation of the DNA molecule to encode a mutant polypeptide antibody and wherein upon introduction of the vector into at least a portion of said plurality of host cells, expression of the reporter gene is induced upon binding of the polypeptide monobody of the second fusion polypeptide to the nuclear receptor, or fragment thereof, of the first fusion polypeptide such that the transcriptional activation domain of the second fusion polypeptide is in sufficient proximity to the DNA-binding domain of the first fusion polypeptide. - View Dependent Claims (85, 86)
-
-
87. A method of validating target protein activity comprising:
-
exposing a target protein to a polypeptide monobody which binds to the target protein and determining whether binding of the target protein by the polypeptide monobody modifies target protein activity. - View Dependent Claims (88, 89, 90, 91, 92, 93, 94, 95)
-
-
96. A method of measuring polypeptide monobody binding affinity for a target protein, said method comprising:
-
exposing a target protein to an interaction partner which binds the target protein and a polypeptide monobody which binds the target protein and measuring the degree to which the polypeptide monobody competes with the interaction partner. - View Dependent Claims (97, 98, 99, 100, 101, 102)
-
-
103. A method of modulating target protein activity comprising:
exposing a target protein to a polypeptide monobody which binds the target protein under conditions effective to modify target protein activity. - View Dependent Claims (104, 105, 106, 107, 108)
Specification